Trial
NCT03363776
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Cancer
Intervention
BMS-986277
Why stopped
Business objectives have changed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-19